Bioretec Accelerates Development of RemeOs Spinal Interbody Cage Following FDA Breakthrough Designation
核心洞察
Bioretec (搜索) is expediting the development of its RemeOs™ Spinal Interbody Cage (搜索), a device utilizing a magnesium alloy-based absorbable hybrid composite.
The decision follows the FDA's Breakthrough Device designation in March 2024, highlighting the device's potential in spinal surgery.
The RemeOs™ cage aims to restore intervertebral height and facilitate fusion in the cervical spine, addressing limitations of traditional implants.
Bioretec (搜索) has announced an acceleration in the product development of its RemeOs™ Spinal Interbody Cage (搜索), an innovative medical device designed for spinal fusion. This decision follows the Breakthrough Device designation granted by the U.S. Food and Drug Administration (FDA) in March 2024, underscoring the device's potential to revolutionize spinal surgery.
The RemeOs™ Spinal Interbody Cage (搜索) is engineered from a multifunctional, MRI-compatible, absorbable hybrid composite based on Bioretec (搜索)'s proprietary magnesium alloy. It is designed to restore intervertebral height and facilitate intervertebral body fusion in the cervical spine. The device aims to overcome the limitations of traditional non-degradable implants by minimizing complications and enhancing patient quality of life.
Addressing Limitations of Current Spinal Implants
Traditional spinal implants often lead to complications such as stress shielding and the need for subsequent removal surgeries. The RemeOs™ cage addresses these issues through its unique absorbable design, which promotes bone growth and reduces stress shielding. This innovative approach has garnered significant interest from medical experts, who have provided positive feedback on its potential applications and benefits within the medical field.
Market Opportunity and Financial Strategy
Bioretec (搜索) anticipates that the RemeOs™ Spinal Interbody Cage (搜索) will revolutionize the treatment of spinal conditions. The company estimates the addressable market for the device to reach approximately EUR 2.3 billion in 2028. Furthermore, the total addressable market for RemeOs™ hybrid composite-based applications in spinal indications is projected to be around EUR 8.1 billion in 2028, presenting a substantial commercial opportunity for Bioretec.
To support the accelerated product development, Bioretec (搜索) is evaluating various financing alternatives and has enlisted Danske Bank A/S, Finland Branch, as its financial advisor. The company's board of directors has updated the company's financial targets in line with the revised overall product development strategy. Details on the updated financial targets will be disclosed in a separate announcement.
Analyst and Investor Briefing
Bioretec (搜索) will host a live webcast briefing on Monday, October 7, 2024, at 2:30 p.m. EEST to discuss the updated product development strategy. The presentation will be held in English. Interested parties can access the webcast and investor presentation through the links provided on Bioretec's website.